A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadeq
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme LLC.
Start Date
May 24, 2024
End Date
May 31, 2029
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme LLC.
Start Date
May 24, 2024
End Date
May 31, 2029